JP2017504571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504571A5 JP2017504571A5 JP2016534731A JP2016534731A JP2017504571A5 JP 2017504571 A5 JP2017504571 A5 JP 2017504571A5 JP 2016534731 A JP2016534731 A JP 2016534731A JP 2016534731 A JP2016534731 A JP 2016534731A JP 2017504571 A5 JP2017504571 A5 JP 2017504571A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- item
- group
- pharmaceutically acceptable
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 107
- 150000003839 salts Chemical class 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 12
- OZAYOHJGXLWETR-QGZVFWFLSA-N 4-[(3R)-1-[(2-chloro-4-fluorophenyl)methyl]piperidin-3-yl]oxy-5-cyclopropyl-2-fluoro-N-methylsulfonylbenzamide Chemical compound ClC1=C(CN2C[C@@H](CCC2)OC2=CC(=C(C(=O)NS(=O)(=O)C)C=C2C2CC2)F)C=CC(=C1)F OZAYOHJGXLWETR-QGZVFWFLSA-N 0.000 claims 3
- PRCIGHMFXRYAIG-INIZCTEOSA-N 5-cyclopropyl-N-cyclopropylsulfonyl-4-[[1-[(1S)-1-(3,5-dichlorophenyl)ethyl]piperidin-4-yl]methoxy]-2-fluorobenzamide Chemical compound C1(CC1)C=1C(=CC(=C(C(=O)NS(=O)(=O)C2CC2)C=1)F)OCC1CCN(CC1)[C@@H](C)C1=CC(=CC(=C1)Cl)Cl PRCIGHMFXRYAIG-INIZCTEOSA-N 0.000 claims 3
- KRNHAUPCKRIYSK-LJQANCHMSA-N N-(azetidin-1-ylsulfonyl)-4-[(3R)-1-[(2-chloro-4-fluorophenyl)methyl]piperidin-3-yl]oxy-5-cyclopropyl-2-fluorobenzamide Chemical compound FC1=CC=C(CN2CCC[C@H](C2)OC2=CC(F)=C(C=C2C2CC2)C(=O)NS(=O)(=O)N2CCC2)C(Cl)=C1 KRNHAUPCKRIYSK-LJQANCHMSA-N 0.000 claims 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- CIXVIWMKNATLIZ-CRAIPNDOSA-N 4-[(3R)-1-[(1R)-1-(5-chloro-6-cyclopropylpyridin-2-yl)ethyl]piperidin-3-yl]oxy-5-cyclopropyl-2-fluoro-N-methylsulfonylbenzamide Chemical compound ClC=1C=CC(=NC=1C1CC1)[C@@H](C)N1C[C@@H](CCC1)OC1=CC(=C(C(=O)NS(=O)(=O)C)C=C1C1CC1)F CIXVIWMKNATLIZ-CRAIPNDOSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 description 75
- 125000000217 alkyl group Chemical group 0.000 description 56
- -1 C1-8Alkyl Chemical group 0.000 description 52
- 125000003545 alkoxy group Chemical group 0.000 description 52
- 229910052739 hydrogen Inorganic materials 0.000 description 51
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 44
- 208000002193 Pain Diseases 0.000 description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 38
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 description 35
- 125000004419 alkynylene group Chemical group 0.000 description 30
- 239000001257 hydrogen Substances 0.000 description 30
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 30
- 125000000623 heterocyclic group Chemical group 0.000 description 25
- 125000001188 haloalkyl group Chemical group 0.000 description 24
- 125000005843 halogen group Chemical group 0.000 description 24
- 238000000034 method Methods 0.000 description 20
- 125000002947 alkylene group Chemical group 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 125000004663 dialkyl amino group Chemical group 0.000 description 15
- 125000004450 alkenylene group Chemical group 0.000 description 14
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 125000004404 heteroalkyl group Chemical group 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 125000003282 alkyl amino group Chemical group 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000004474 heteroalkylene group Chemical group 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 206010065390 Inflammatory pain Diseases 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 description 3
- 206010020844 Hyperthermia malignant Diseases 0.000 description 3
- 208000007914 Labor Pain Diseases 0.000 description 3
- 208000035945 Labour pain Diseases 0.000 description 3
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 description 3
- 208000026709 Liddle syndrome Diseases 0.000 description 3
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 206010061533 Myotonia Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 3
- 206010029279 Neurogenic bladder Diseases 0.000 description 3
- 208000012075 Paroxysmal dystonia Diseases 0.000 description 3
- 208000010886 Peripheral nerve injury Diseases 0.000 description 3
- 208000004983 Phantom Limb Diseases 0.000 description 3
- 206010056238 Phantom pain Diseases 0.000 description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- 206010037113 Pseudoaldosteronism Diseases 0.000 description 3
- 208000005793 Restless legs syndrome Diseases 0.000 description 3
- 206010039020 Rhabdomyolysis Diseases 0.000 description 3
- 206010040744 Sinus headache Diseases 0.000 description 3
- 108010052164 Sodium Channels Proteins 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 206010043269 Tension headache Diseases 0.000 description 3
- 208000008548 Tension-Type Headache Diseases 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000010118 dystonia Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 201000007004 malignant hyperthermia Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 230000036473 myasthenia Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- 208000009935 visceral pain Diseases 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 150000001539 azetidines Chemical class 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 208000019865 paroxysmal extreme pain disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/001452 | 2013-11-27 | ||
| CN2013001452 | 2013-11-27 | ||
| CN2013088062 | 2013-11-28 | ||
| CNPCT/CN2013/088062 | 2013-11-28 | ||
| CN2014090171 | 2014-11-03 | ||
| CNPCT/CN2014/090171 | 2014-11-03 | ||
| PCT/CN2014/092269 WO2015078374A1 (en) | 2013-11-27 | 2014-11-26 | Substituted benzamides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018146542A Division JP2018188466A (ja) | 2013-11-27 | 2018-08-03 | 置換ベンズアミド及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504571A JP2017504571A (ja) | 2017-02-09 |
| JP2017504571A5 true JP2017504571A5 (https=) | 2017-12-28 |
| JP6383418B2 JP6383418B2 (ja) | 2018-08-29 |
Family
ID=53198372
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534731A Expired - Fee Related JP6383418B2 (ja) | 2013-11-27 | 2014-11-26 | 置換ベンズアミド及びその使用方法 |
| JP2018146542A Pending JP2018188466A (ja) | 2013-11-27 | 2018-08-03 | 置換ベンズアミド及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018146542A Pending JP2018188466A (ja) | 2013-11-27 | 2018-08-03 | 置換ベンズアミド及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9546164B2 (https=) |
| EP (2) | EP3074377B1 (https=) |
| JP (2) | JP6383418B2 (https=) |
| KR (1) | KR20160090846A (https=) |
| CN (1) | CN105793238B (https=) |
| AU (1) | AU2014356967A1 (https=) |
| CA (1) | CA2931732A1 (https=) |
| CL (1) | CL2016001287A1 (https=) |
| CR (1) | CR20160296A (https=) |
| EA (1) | EA201691085A1 (https=) |
| IL (1) | IL245844A0 (https=) |
| MX (1) | MX2016006936A (https=) |
| PE (1) | PE20161247A1 (https=) |
| PH (1) | PH12016501007A1 (https=) |
| TW (1) | TWI560180B (https=) |
| WO (1) | WO2015078374A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| CN104718188B (zh) * | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| WO2016124140A1 (zh) * | 2015-02-04 | 2016-08-11 | 上海海雁医药科技有限公司 | 杂环取代的n-磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| HK1252567A1 (zh) * | 2015-05-22 | 2019-05-31 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| DK3373931T3 (da) * | 2015-11-13 | 2022-11-28 | Oppilan Pharma Ltd | Heterocykliske forbindelser til behandling af sygdom |
| EP3380466A1 (en) * | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| WO2017095723A1 (en) * | 2015-11-30 | 2017-06-08 | Merck Sharp & Dohme Corp. | Aryl acylsulfonamides as blt1 antagonists |
| AU2016370554B2 (en) | 2015-12-18 | 2018-11-29 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| KR20180086259A (ko) | 2016-02-03 | 2018-07-30 | 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 | 헤테로 고리로 치환된 n-설포닐벤즈아미드 유도체, 이의 제조 방법과 약학적 용도 |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| PL3458449T3 (pl) | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| PE20190980A1 (es) * | 2016-10-17 | 2019-07-09 | Genentech Inc | Compuestos terapeuticos y metodos para utilizarlos |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| US12600726B2 (en) | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CN110300745B (zh) * | 2017-07-24 | 2023-03-31 | 上海海雁医药科技有限公司 | 钠离子通道抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| WO2019045035A1 (en) | 2017-08-31 | 2019-03-07 | Raqualia Pharma Inc. | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS |
| CN109574927A (zh) * | 2017-09-29 | 2019-04-05 | 浙江海正药业股份有限公司 | N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途 |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| WO2020248123A1 (en) | 2019-06-11 | 2020-12-17 | Merck Sharp & Dohme Corp. | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20230399319A1 (en) * | 2019-12-27 | 2023-12-14 | Japan Tobacco Inc. | Acylsulfamide Compound and Pharmaceutical Use Therefor |
| CN111303120A (zh) * | 2020-03-14 | 2020-06-19 | 江巨东 | 一种盐酸法舒地尔的制备方法 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| CN115215787A (zh) * | 2021-04-19 | 2022-10-21 | 中国科学院上海药物研究所 | 生长抑素受体5拮抗剂及其用途 |
| US12018016B2 (en) | 2021-08-18 | 2024-06-25 | Amgen Inc. | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors |
| WO2023023534A2 (en) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl compounds as ccr6 inhibitors |
| EP4174077A1 (en) * | 2021-10-27 | 2023-05-03 | Merck Patent GmbH | Electronic switching device |
| CN116120261B (zh) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | 一种3-[（4-磺胺哌嗪-1-基）甲基]苯甲酸类化合物的制备方法 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3705185A (en) | 1969-04-14 | 1972-12-05 | Minnesota Mining & Mfg | N-aroyl sulfonamides |
| GR71915B (https=) * | 1979-11-27 | 1983-08-16 | Pfizer | |
| GB8524157D0 (en) | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
| DK24089D0 (da) | 1989-01-20 | 1989-01-20 | Hans Bundgaard | Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups |
| GB8911854D0 (en) | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
| IL101860A0 (en) | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| FI952481A0 (fi) | 1992-11-23 | 1995-05-22 | Hoechst Roussel Pharma | Substituoituja 3-(aminoalkyyliamino)-1,2-bentsisoksatoleja ja niihin liittyviä yhdisteitä |
| US5573653A (en) | 1994-07-11 | 1996-11-12 | Sandoz Ltd. | Electrochemical process for thiocyanating aminobenzene compounds |
| HU221138B1 (en) | 1994-08-30 | 2002-08-28 | Sankyo Co | Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| US5753653A (en) | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| KR100789567B1 (ko) | 2001-11-06 | 2007-12-28 | 동화약품공업주식회사 | 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도 |
| DE10201550A1 (de) | 2002-01-17 | 2003-07-31 | Merck Patent Gmbh | Phenoxy-Piperidine |
| ATE449099T1 (de) | 2002-08-08 | 2009-12-15 | Memory Pharm Corp | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren |
| PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
| WO2004092145A1 (en) | 2003-04-15 | 2004-10-28 | Pfizer Inc. | Alpha substituted carboxylic acid as ppar modulators |
| US8202861B2 (en) | 2003-08-08 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| CN101643458A (zh) | 2003-08-08 | 2010-02-10 | 沃泰克斯药物股份有限公司 | 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物 |
| AU2004278030C1 (en) | 2003-10-03 | 2010-12-02 | Portola Pharmaceuticals, Inc. | 2,4-Dioxo-3-quinazolinylaryl sulfonylureas |
| US7081539B2 (en) | 2004-03-25 | 2006-07-25 | Dainippon Sumitomo Pharma Co., Ltd. | One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide |
| EP1773792A1 (en) | 2004-07-30 | 2007-04-18 | Merck & Co., Inc. | Indanone potentiators of metabotropic glutamate receptors |
| WO2006020830A2 (en) | 2004-08-12 | 2006-02-23 | Amgen Inc. | Bisaryl-sulfonamides |
| CN101031565B (zh) | 2004-09-29 | 2010-09-29 | 博尔托拉制药公司 | 取代的2h-1,3-苯并噁嗪-4(3h)-酮 |
| JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| EP1922311A2 (en) | 2005-09-09 | 2008-05-21 | Brystol-Myers Squibb Company | Acyclic ikur inhibitors |
| AU2006303367A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors |
| CA2630234A1 (en) | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| AR058296A1 (es) | 2005-12-09 | 2008-01-30 | Kalypsys Inc | Inhibidores de histona desacetilasa y composicion farmaceutica |
| CA2648202A1 (en) | 2006-04-11 | 2007-10-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| EP2086973B1 (en) | 2006-10-11 | 2012-01-25 | Amgen Inc., | Imidazo- and triazolo-pyridine compounds and methods of use therof |
| EP2108019A2 (en) | 2007-01-30 | 2009-10-14 | Biogen Idec MA, Inc. | 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases |
| AR065194A1 (es) | 2007-02-05 | 2009-05-20 | Xenon Pharmaceuticals Inc | Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio |
| JP5361857B2 (ja) | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | イオンチャネルの阻害剤 |
| AU2008256937A1 (en) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| CN101679262A (zh) | 2007-06-07 | 2010-03-24 | 安斯泰来制药株式会社 | 吡啶酮化合物 |
| US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
| CA2693588C (en) | 2007-07-13 | 2015-11-17 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009010784A1 (en) | 2007-07-13 | 2009-01-22 | Astrazeneca Ab | New compounds 955 |
| WO2009022730A1 (ja) | 2007-08-10 | 2009-02-19 | Nippon Chemiphar Co., Ltd. | Ｐ２ｘ４受容体拮抗剤 |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| MX2010009561A (es) * | 2008-02-29 | 2010-09-24 | Renovis Inc | Compuestos amida, composiciones y usos de los mismos. |
| JP5304785B2 (ja) | 2008-06-23 | 2013-10-02 | アステラス製薬株式会社 | スルホンアミド化合物又はその塩 |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2011016234A1 (en) | 2009-08-04 | 2011-02-10 | Raqualia Pharma Inc. | Picolinamide derivatives as ttx-s blockers |
| BR112012006686B8 (pt) | 2009-09-25 | 2021-05-25 | Astellas Pharma Inc | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa |
| WO2011059042A1 (ja) | 2009-11-12 | 2011-05-19 | 武田薬品工業株式会社 | 芳香環化合物 |
| US8471034B2 (en) | 2009-11-18 | 2013-06-25 | Concert Pharmaceuticals, Inc. | Niacin prodrugs and deuterated versions thereof |
| TW201139406A (en) | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| EP2533638B1 (en) | 2010-02-12 | 2016-02-10 | Nivalis Therapeutics, Inc. | Novel s-nitrosoglutathione reductase inhibitors |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| WO2012005842A1 (en) | 2010-06-30 | 2012-01-12 | Cardiac Pacemakers, Inc. | Lead having coil electrode with preferential bending region |
| WO2012004664A2 (en) | 2010-07-07 | 2012-01-12 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| WO2012004714A2 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Chemical compounds |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| US9102621B2 (en) * | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
| ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
| JP2013532185A (ja) * | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 化合物 |
| JP2013532184A (ja) | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| EP2593433B1 (en) * | 2010-07-12 | 2014-11-26 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| JP2013531687A (ja) | 2010-07-16 | 2013-08-08 | パーデュー、ファーマ、リミテッド、パートナーシップ | ナトリウムチャネル遮断剤としてのピリジン化合物 |
| CN103221408A (zh) | 2010-09-13 | 2013-07-24 | 诺瓦提斯公司 | 三嗪-*二唑类化合物 |
| WO2012039657A1 (en) | 2010-09-22 | 2012-03-29 | Astrazeneca Ab | Novel chromane compound for the treatment of pain disorders |
| CN103429571A (zh) | 2010-12-22 | 2013-12-04 | 普渡制药公司 | 作为钠通道阻断剂的取代吡啶 |
| WO2012095781A1 (en) | 2011-01-13 | 2012-07-19 | Pfizer Limited | Indazole derivatives as sodium channel inhibitors |
| MX355907B (es) | 2011-02-02 | 2018-05-04 | Vertex Pharma | Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos. |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| WO2013056232A2 (en) | 2011-10-13 | 2013-04-18 | Case Western Reserve University | Rxr agonists compounds and methods |
| JP2014532660A (ja) | 2011-10-28 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物 |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| US9133131B2 (en) | 2011-11-15 | 2015-09-15 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| CA2857603C (en) * | 2011-12-15 | 2016-08-02 | Pfizer Limited | Sulfonamide derivatives |
| US20150291514A1 (en) | 2012-01-04 | 2015-10-15 | Pfizer Limted | N-Aminosulfonyl Benzamides |
| JP2015083542A (ja) * | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| WO2013146969A1 (ja) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規二置換シクロヘキサン誘導体 |
| CN104718188B (zh) * | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR101663436B1 (ko) * | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| US9758480B2 (en) * | 2012-07-19 | 2017-09-12 | Sumitomo Dainippon Pharma Co., Ltd. | 1-(cycloalkyl-carbonyl)proline derivative |
| JP2015535252A (ja) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物 |
| EP2911668A4 (en) | 2012-10-26 | 2016-07-20 | Merck Sharp & Dohme | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS |
| WO2014096941A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| KR102295748B1 (ko) | 2013-01-31 | 2021-09-01 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드 |
| US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| CA2900604A1 (en) | 2013-03-15 | 2014-09-25 | Chromocell Corporation | Sodium channel modulators for the treatment of pain |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| WO2015051043A1 (en) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
-
2014
- 2014-11-26 WO PCT/CN2014/092269 patent/WO2015078374A1/en not_active Ceased
- 2014-11-26 CA CA2931732A patent/CA2931732A1/en not_active Abandoned
- 2014-11-26 MX MX2016006936A patent/MX2016006936A/es unknown
- 2014-11-26 JP JP2016534731A patent/JP6383418B2/ja not_active Expired - Fee Related
- 2014-11-26 AU AU2014356967A patent/AU2014356967A1/en not_active Abandoned
- 2014-11-26 CN CN201480064734.4A patent/CN105793238B/zh not_active Expired - Fee Related
- 2014-11-26 EP EP14865855.2A patent/EP3074377B1/en active Active
- 2014-11-26 KR KR1020167016643A patent/KR20160090846A/ko not_active Withdrawn
- 2014-11-26 EP EP18197734.9A patent/EP3450428A1/en not_active Withdrawn
- 2014-11-26 PE PE2016000696A patent/PE20161247A1/es not_active Application Discontinuation
- 2014-11-26 CR CR20160296A patent/CR20160296A/es unknown
- 2014-11-26 EA EA201691085A patent/EA201691085A1/ru unknown
- 2014-11-27 TW TW103141262A patent/TWI560180B/zh not_active IP Right Cessation
-
2015
- 2015-01-22 US US14/603,273 patent/US9546164B2/en not_active Expired - Fee Related
-
2016
- 2016-05-25 IL IL245844A patent/IL245844A0/en unknown
- 2016-05-26 CL CL2016001287A patent/CL2016001287A1/es unknown
- 2016-05-27 PH PH12016501007A patent/PH12016501007A1/en unknown
- 2016-09-23 US US15/275,131 patent/US9694002B2/en not_active Expired - Fee Related
-
2018
- 2018-08-03 JP JP2018146542A patent/JP2018188466A/ja active Pending
-
2019
- 2019-04-22 US US16/390,957 patent/US20200108054A1/en not_active Abandoned
- 2019-11-07 US US16/677,487 patent/US20210093618A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504571A5 (https=) | ||
| AU2013370300B2 (en) | Novel antiviral agents against HBV infection | |
| JP2015523369A5 (https=) | ||
| CA3105748A1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| RU2014121984A (ru) | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств | |
| TW201716397A (zh) | 作為組蛋白去乙醯酶6抑制劑之 二唑胺衍生物及含彼之醫藥組合物 | |
| CA2570999A1 (en) | Compounds, compositions and methods | |
| AU2016299486A1 (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2014532640A5 (https=) | ||
| RS60569B1 (sr) | Jedinjenja karbamata i postupci njihovog pravljenja i upotrebe | |
| CN107001372A (zh) | 取代的氨基嘌呤化合物、其组合物及其治疗方法 | |
| EA007297B1 (ru) | Производные n-бифенилметиламиноциклоалканкарбоксамида с заместителем на метиле в качестве антагонистов брадикинина | |
| AU2017207991A1 (en) | Pyridazine derivatives as EAAT2 activators | |
| JP2017516819A (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキルおよびアリール誘導体 | |
| JP2017516818A (ja) | 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアルキル誘導体 | |
| BR112018069930B1 (pt) | Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica | |
| RU2018124591A (ru) | Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение | |
| RU2013130019A (ru) | Новые производные азетидина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) | |
| US20210040034A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| CN119110795A (zh) | 用于治疗与lpa受体活性相关的病症的化合物和组合物 | |
| ES2363565T3 (es) | Acetofenonas sustituidas útiles como inhibidores de pde4. | |
| CN111936488B (zh) | 用于治疗寄生虫感染的新颖化合物 | |
| CN113045487A (zh) | 一种选择性钠通道调节剂及其制备和应用 | |
| AU2018223177B2 (en) | Aromatic compounds which enhance notch signaling, for use in therapy | |
| US9856250B2 (en) | Substituted tropane derivatives |